Delayed Neurobehavioral Development in Children Born to Pregnant Women with Mild Hypothyroxinemia During the First Month of Gestation: The Importance of Early Iodine Supplementation

Pere Berbel,1 José Luis Mestre,2,* Asunción Santamaría,1,3 Inmaculada Palazón,4 Ascensión Franco,1 Marisa Graells,5,6 Antonio González-Torga,6 and Gabriella Morreale de Escobar7

Background: Maternal hypothyroxinemia, due to gestational iodine deficiency, causes neurological dysfunctions in the progeny. Our aim was to determine the effects of delayed iodine supplementation (200 μg KI per day) to mildly hypothyroxinemic pregnant women at the beginning of gestation (i.e., having circulating free thyroxine [FT₄] within the 0th–10th percentile interval and normal thyrotropin [TSH]) on the neurobehavioral development of their children.

Methods: Using the Brunet–Lézine scale, we evaluated the neurocognitive performance at 18 months of age in three groups of children. Group 1 included children of women with FT₄ above the 20th percentile at 4–6 gestational weeks and at full-term. Group 2 included children of mildly hypothyroxinemic women diagnosed during the first 12–14 gestational weeks and with FT₄ above the 20th percentile at full-term. Group 3 included children born to mildly hypothyroxinemic women at full-term, without iodine supplementation during gestation. Women of all groups were iodine supplemented from the day of enrollment until the end of lactation.

Results: Before iodine supplementation, 33.0% of the women (114 out of 345) were hypothyroxinemic, with FT₄ below normal in 28 of them (8.1%). None were found to be hypothyroxinemic at full-term after supplementation. The mean (±SD) developmental quotient of children was 101.8 ± 9.7 in group 1 (n = 13) vs. 87.5 ± 8.9 in group 3 (n = 19; p < 0.001) and 92.2 ± 5.4 in group 2 (n = 12; p < 0.05). The difference between groups 2 and 3 was not statistically significant. Delayed neurobehavioral performance was observed in 36.8% and 25.0% of children in groups 3 and 2, respectively, compared with no children in group 1. Differences (p < 0.001) were found on gross and fine motor coordination and socialization quotients. No statistically significant differences were found on language quotients.

Conclusions: A delay of 6–10 weeks in iodine supplementation of hypothyroxinemic mothers at the beginning of gestation increases the risk of neurodevelopmental delay in the progeny. Public health programs should address the growing problem of iodine deficiency among women of gestational age in developing and industrialized nations.

Introduction

Iodine deficiency is one of the most frequent causes worldwide of preventable mental retardation in children. A wide spectrum of iodine deficiency disorders has been described during gestation, ranging from abortion to congenital anomalies, deafness, neurological cretinism, neurocognitive delay, and mental retardation, as well as attention deficit hyperactivity disorder, among others (1,2). In children, the severity of the neurodevelopmental damage caused by iodine deficiency during gestation depends on the developmental period affected by this condition and on its severity.

*Present address: Pediatrics, Hospital Universitario de Sant Joan, Sant Joan d’Alacant, Alicante, Spain.
1Instituto de Neurociencias de Alicante, Universidad Miguel Hernández and Consejo Superior de Investigaciones Científicas (CSIC), Alicante, Spain.
2Obstetrics, Gynecology and Pediatrics, Hospital Marina Baixa, La Vila Joiosa, Alicante, Spain.
3Center of Primary Health Care “Foietes”, Benidorm, Alicante, Spain.
4Pediatrics, Clinical Child Psychology, Hospital General Universitario, Alicante, Spain.
5Biochemistry Laboratory, Hospital Marina Baixa, La Vila Joiosa, Alicante, Spain.
6Preventive Medicine, Hospital General Universitario, Alicante, Spain.
7Instituto de Investigaciones Biomédicas “Alberto Sols”, CSIC and Universidad Autónoma de Madrid, Madrid, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain.
Iodine is an essential component of the thyroid hormones, thyroxine (T₄) and triiodothyronine (T₃). Iodine intake is especially crucial during gestation and lactation, since during these developmental periods the mother is the only source of iodine for the fetus and the neonate. Most critical for brain development is the fact that T₃ (the active hormone interacting with nuclear thyroid receptors) is produced by the fetus from maternal T₄ and this is the only source of T₄ for the fetus during the first trimester of pregnancy (3–7). During this period, fundamental processes occur in the development of the fetal central nervous system. In particular, the cerebral vesicles, from which the cerebral cortex develops, become recognizable in the developing central nervous system by embryonic day 35 and the neocortical development begins by embryonic day 46 (8). The concentration of T₃ nuclear receptors is low at the beginning of neocortical development but it progressively increases 10-fold by the 16th week of gestation (9), in parallel to neuroblast proliferation and neuronal migration (8). This makes the human brain especially vulnerable during development to deficiencies of iodine and thyroid hormones, not only because of their action through nuclear receptors (9,10), but also for their possible nongenomic effects that might take place even earlier. For instance, recent studies have shown that thyroid hormone can link integrin αVβ3 receptor, which may induce angiogenesis by activation of the mitogen-activated protein kinase signal transduction cascade (11).

Epidemiological studies have shown neurological alterations in children born to mildly to moderately hypothyroxinemic mothers: at least 50% of the offspring of women with mild to moderate iodine deficiency during the first trimester had delayed neurobehavioral development (12–15). An important prospective study disclosed that the children of mothers suffering mild to moderate iodine deficiency during the first trimester had an intelligence quotient (IQ) that was 10–15 points below the normal mean values and that 11 of 16 children of the moderately iodine-deficient area (68.7%) presented attention deficit/hyperactivity disorder (16). In contrast, none of the children from mothers who were not hypothyroxinemic during the first trimester had this syndrome.

Experimental studies performed in rodents are consistent with the results from epidemiological studies: the tangential and radial migrations of cortical neurons in the pups of hypothyroxinemic dams are abnormal resulting in ectopic neurons in different cortical layers, especially in the subcortical white matter and in the alveus of the hippocampus. These ectopias were found even when the maternal hypothyroxinemia was mild and transient at the beginning of corticogenesis (17–20). Whether or not such a critical period also exists in humans at the beginning of corticogenesis is unknown.

We here explore if mild and transient hypothyroxinemia in pregnant women during the first trimester of gestation in a mildly iodine-deficient region, when the bulk of fetal neocortical proliferation has already occurred, may affect the neurobehavioral development of their children.

**Subjects and Methods**

**Subjects**

This study was performed in the area of Marina Baixa (Alicante, Spain). Three groups of pregnant women were included (Table 1) and neurocognitive evaluation of strictly selected children (Table 2) was performed at 18 months of age. These women were enrolled during the first 2–3 months after the beginning of this study. Women of groups 1 and 2 were enrolled at their first pregnancy visit (by a midwife or gynecologist); women of group 3 were enrolled at full-term. All women were supplemented orally with iodine (200 μg KI per day) from the day of enrollment to the end of lactation. The

<table>
<thead>
<tr>
<th>Group 1 KI from</th>
<th>Group 2 KI from</th>
<th>Group 3 KI after delivery</th>
</tr>
</thead>
<tbody>
<tr>
<td>4–6 GW (n = 92)</td>
<td>12–14 GW (n = 102)</td>
<td>delivery (n = 151)</td>
</tr>
<tr>
<td>At 4–6 GW</td>
<td>At term</td>
<td>At 12–14 GW</td>
</tr>
<tr>
<td>No hypothyroxinemia</td>
<td>FT₄ (20th–100th); normal TSH</td>
<td>FT₄ (10th–20th); normal TSH</td>
</tr>
<tr>
<td>64 (69.6%)</td>
<td>46 (50.0%)</td>
<td>17 (18.5%)</td>
</tr>
<tr>
<td>45 (100.0%)</td>
<td>43 (95.6%)</td>
<td>2 (4.4%)</td>
</tr>
<tr>
<td>FT₄ (0th–10th); normal TSH</td>
<td>28 (30.4%)</td>
<td>22 (23.9%)</td>
</tr>
<tr>
<td>Hypothyroxinemia</td>
<td>28 (30.4%)</td>
<td>22 (23.9%)</td>
</tr>
<tr>
<td>FT₄ &lt;0.71; normal TSH</td>
<td>22 (23.9%)</td>
<td>21 (46.2%)</td>
</tr>
<tr>
<td>FT₄ &lt;0.71; TSH &gt;4.80</td>
<td>6 (6.5%)</td>
<td>1 (1.0%)</td>
</tr>
</tbody>
</table>

The FT₄ concentration limits for the 0th–10th percentile interval are 0.71 and 0.82 ng/dL; for the 10th–20th percentile interval, 0.83 and 0.91 ng/dL; and for the 20th–100th percentile interval, 0.92 and 1.85 ng/dL. The normal range for FT₄ is 0.71–1.85 ng/dL and for TSH is 0.38–4.80 μU/mL. The groups from which the neurocognitive evaluated children were derived are indicated in bold.

aOnly women with FT₄ within the 20th–100th percentile interval at 4–6 GW and with normal TSH are included in this column, one woman that had a spontaneous abortion being excluded.

bOnly hypothyroxinemic women at 12–14 GW with normal TSH are included in this column, one woman with TSH above the normal range being excluded.

Table 1. Number of Mothers with Different Serum Concentrations of Free Thyroxine and Thyrotropin at Different Gestational Weeks.

GW, gestational week; FT₄, free thyroxine; TSH, thyrotropin.
procedures followed were in accordance with the ethical standards of the European Union on human experimentation and approved by the Ethics Committee of the University Miguel Hernández.

Group 1 (Table 1) consisted of 92 women who were enrolled at 4–6 gestational weeks. They were then supplemented with iodine (200 \( \mu g \) KI per day) until full-term and throughout lactation, with the exception of five cases with abnormal TSH (three women with TSH >4.84 \( \mu U/mL \)), who were referred to an endocrinologist and excluded from the group. Neurocognitively evaluated children (12 of 21 children) were born to mildly hypothyroxinemic women with normal TSH and with FT\(_4\) within the 0th–10th percentile interval during the first trimester, and FT\(_4\) above the 20th percentile at full-term, and not affected by the exclusion criteria (9 of 21 children; Table 3).

Group 2 (Table 1) consisted of 102 women enrolled at the beginning of the second trimester (12–14 gestational weeks). They were then supplemented with iodine (200 \( \mu g \) KI per day) until full-term and throughout lactation, with the exception of two cases with TSH >4.84 \( \mu U/mL \), who were referred to an endocrinologist and excluded from the group. Neurocognitively evaluated children (12 of 21 children) were born to mildly hypothyroxinemic women with normal TSH and with FT\(_4\) within the 0th–10th percentile interval during the first trimester, and FT\(_4\) above the 20th percentile at full-term, and not affected by the exclusion criteria (9 of 21 children; Table 3).

Group 3 (Table 1) consisted of 151 women enrolled at full-term (37–40 gestational weeks); they were then supplemented with iodine (200 \( \mu g \) KI per day) throughout lactation, with the exception of five cases with abnormal TSH (three women with TSH >4.84 \( \mu U/mL \), and two with TSH <0.38 \( \mu U/mL \)), who were referred to an endocrinologist and excluded from the group. We performed neurocognitive evaluations on selected children (19 of 41 children; two children were twins) born to mildly hypothyroxinemic women at full-term defined as having normal TSH and FT\(_4\) within the 0th–10th percentile interval, and who did not meet any of the exclusion criteria (22 of 41 children; Table 3) defined in the exclusion criteria given further on and in Table 2.

Thyroid function in all newborns was checked by the Neonatal Thyroid Screening Program, based on circulating TSH. No cases of congenital hypothyroidism were disclosed. No further measurements of thyroid function were performed in the children, although they were carefully evaluated every 3 months, until the 18th month of age, by the pediatrician involved in this project, focusing on detection of possible signs of thyroid malfunction. None of the evaluated children showed signs of hyper- or hypothyroidism and all children who were later evaluated for their neurobehavior were breastfed for at least the first 6 months of postnatal life (Table 2).

### Inclusion criteria

We included (i) pregnant women above the 20th percentile at 4–6 gestational weeks and at full-term; (ii) pregnant women with mild hypothyroxinemia as defined by FT\(_4\) levels within the 0th–10th percentile interval of the normal distribution and with normal TSH values at the end of the first trimester, and with FT\(_4\) above the 20th percentile at full-term; and (iii) pregnant women with mild hypothyroxinemia at full-term, as just defined in (ii).

### Exclusion criteria

We established these criteria to obtain comparably homogeneous groups of children excluding as many adverse factors as possible (other than maternal hypothyroxinemia; Table 1) that might affect both pre- and post-natal neurobehavioral development of the child. These criteria are indicated in Table 2 and concern the medical history during gestation, at delivery, and during lactation, including nutritional habits of pregnant women and their intake of drugs, the health of children until neurocognitive evaluation, and the socio-economic environment of the family.

<table>
<thead>
<tr>
<th>Cause for exclusion</th>
<th>Group 1 (n = 43)(^a)</th>
<th>Group 2 (n = 21)</th>
<th>Group 3 (n = 40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total excluded(^b)</td>
<td>30</td>
<td>9</td>
<td>22</td>
</tr>
<tr>
<td>Delivery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death at birth</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Caesarean section</td>
<td>8</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>Neonatal characteristics(^c)</td>
<td>3</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>APGAR &lt;6 (at 5 min after birth)</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Severe malformation</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Severe disease</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Early postnatal death</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Abstinence syndrome</td>
<td>2</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Lactation and 1st year of life</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactation &lt;6 months</td>
<td>3</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Tonic neck reflex at 8th month</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Hypoacusia</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Severe malformation</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Blindness</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Severe disease</td>
<td>3</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Death</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Poor parental care</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Maternal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight increase(^d)</td>
<td>10</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Toxic habits (drugs):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol(^e)</td>
<td>5</td>
<td>5</td>
<td>9</td>
</tr>
<tr>
<td>Tobacco(^f)</td>
<td>6</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td>Others</td>
<td>6</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>Sociocultural factors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rural</td>
<td>5</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Single parent family</td>
<td>3</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>School education</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>(&lt;14 y)(^g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unemployment(^h)</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Without known profession(^i)</td>
<td>6</td>
<td>2</td>
<td>5</td>
</tr>
</tbody>
</table>

\(^a\)The total number (n) of women per group who passed the inclusion criteria shown in Table 1.

\(^b\)Including the cases that did not return for evaluation of the children (10 cases in group 1, two cases in group 2, and three cases in group 3).

\(^c\)Children with weight outside the 2500–4000 g range, height outside the 47–53 cm range, and cephalic perimeter outside the 33–37 cm range.

\(^d\)Women with weight increase during gestation outside the 6–15 kg range.

\(^e\)Drinking other than 0 mL throughout.

\(^f\)Smoking more than 10 cigarettes per week throughout.

\(^g\)Both parents.
The inter- and intra-assay coefficients of variation were lower than those recommended by the Spanish Scientific Society of Clinical Chemistry and Molecular Biology.

**Statistical analysis**

We used the SYSTAT® statistical package (SYSTAT, Inc., Evanston, IL). Group comparisons were analyzed with the Kolmogorov–Smirnov test and ANOVA using the Kruskal–Wallis test for nonparametric distributions; levels of significance were two-tailed.

**Results**

**Epidemiological data**

The Hospital Marina Baixa has an average of 1300 births per year, 22% of them by cesarean section. Healthy neonates leave the hospital 48–72 hours after birth; 83% are breast-fed on average for 3.1 months. The age of women at full-term ranged from 16 to 44 years (mean 31.1 years) and their weight gain ranged from 6 to 39 kg (mean 12.5 kg). We found that 88% of the women reported eating fish at least twice weekly, 76% drinking daily 0.5 L of milk and milk-derived products, and one was a strict vegetarian. Of the total families, 83% were urban and 21% were single parent. Only 8% of the women were aware of the importance of the iodine intake during gestation and 22% used certified iodized salt.

**Spot iodine screening**

Iodine concentrations (µg/L) of spot urine samples revealed that mean values increased in groups 2 (96.7 ± 39.9; range: 10–220) and 1 (120.5 ± 41.7; range: 20–285) with respect to group 3 (74.6 ± 0.8; range: 10–285; p < 0.001). In group 3, only 4.7% had a urinary iodine >150 µg/L vs. 33.3% in group 2 and 33.4% in group 1. On average, 24.1% had a urinary iodine <50 µg/L in all groups (Fig. 1A).

**Hormone screening before iodine supplementation**

In all groups, the percentage of hypothyroxinemic women with normal TSH was very high (on average 33.0%; Fig. 1A and Table 1). On average, 7.8% of them had FT4 below the normal range. Iodine-sufficient women with FT4 levels above the 20th percentile ranged from 50.0% in group 1 at 4–6 gestational weeks to 39.1% in group 3 at full-term. Abnormal TSH was found in one woman of group 1, two of group 2, and five of group 3 (Table 1).
Effects of iodine supplementation

All supplemented women had normal FT4 above the 10th percentile and normal TSH (Fig. 1C and Table 1). In group 1, 4.4% had FT4 within the 10th–20th percentile interval, whereas in 95.6% it was higher. These values were also high in group 2 (14.3% and 85.7%, respectively) and clearly lower in group 3 (21.2% and 39.1%, respectively). The mean FT4 values (ng/dL) increased in mothers of neurobehavioral evaluated children in group 1 and 2 to 1.03 ± 0.10 and 1.02 ± 0.11 respectively, as compared to the values of mothers in group 3, 0.77 ± 0.04 (p < 0.001; Table 4).

Neurocognitive development

Due to the strict exclusion criteria (Table 2), 13 children in group 1 (14.1%), 12 in group 2 (11.8%), and 19 children in group 3 (11.9%; two children were twins) were included for neurobehavioral evaluation. The mean developmental quotient in group 1 (101.8 ± 9.7) was significantly higher than in groups 3 (87.5 ± 8.9; p < 0.001) and 2 (92.2 ± 15.4; p < 0.05) (Fig. 2A). Differences between groups 2 and 3 were not statistically significant (p = 0.49). Accelerated performance was only found in groups 1 and 2. In group 1, 15.4% of children showed accelerated performance vs. 8.3% in group 2. Normal performance also increased in group 1 (84.6%) with respect to groups 2 (66.7%) and 3 (63.2%; Fig. 2B). Children with delayed performance were only observed in groups 2 (25%) and 3 (36.8%). These differences were also found when comparing quotients in each one of the four scales of the Brunet–Lézine test. Statistically significant differences (p < 0.001) were found in gross and fine motor coordination and socialization scales, with group 1 children obtaining the highest quotients (Fig. 2C). Mean language quotients were not statistically different between groups (p = 0.45).

Discussion

Our results show that a delay in maternal iodine supplementation at the beginning of gestation increases the risk of neurocognitive developmental delay of their offspring. Despite the relatively small number of children evaluated in this study, the developmental differences in those with late supplementation were clearly significant. Also of note is the finding that one third (33.0%) of the total group of pregnant women (n = 345) included in this study had hypothyroxinemia at full-term or earlier in gestation with normal TSH, indicating the high prevalence of dietary iodine deficiency among women of reproductive age in this coastal region of Spain. Children of mothers who suffered mild hypothyroxinemia during the first 12–14 gestational weeks (group 2)
showed lower performances in gross and fine motor coordination and socialization than those born to iodine-sufficient women with FT₄ above the 20th percentile at 4–6 gestational weeks and at full-term (group 1). Performance in these three categories decreased further in children of group 3 women who were not supplemented with iodine during gestation. Iodine supplementation did not cause thyroid function alterations in pregnant women: none of groups 1 and 2 women receiving iodine supplementation were found to be hypothyroxinemic at full-term and none had abnormal FT₄ or TSH.

This study has some unavoidable limitations. The number of mothers and children that passed all the inclusion and exclusion criteria was very low. Owing the low number of deliveries in the Hospital Marina Baixa (on average 1300 births per year), only 345 women could be enrolled when the study was started and 46 women (13.3% of cases) passed the inclusion and exclusion criteria. The number of enrolled mothers per group could have been increased by keeping pregnant women without iodine supplementation but that would not have been ethically acceptable. Likewise, the number of children per group was low due to our strict exclusion criteria, which were established in order to obtain groups of children growing in comparable social environments. Another limiting factor was the determination of the thyroid function in pregnant women and in their children. Concentrations of iodine in spot urine samples are adequate for epidemiological assessments of the iodine intake of populations, but not for that of an individual, as it varies considerably within a day and from day to day. Circulating thyroid hormone determinations are a more accurate procedure to assess thyroid function, and were performed in all women at enrollment and at full-term, assuming that thyroid function was maintained within the obtained values during this period. Confirmation of this assumption by increasing the number of blood samples obtained between enrollment and full-term (a procedure not covered by our Public Health protocols) might have decreased the number of participating women and, as a consequence, that of the children returning for neurobehavioral evaluation. Thyroid function of the children was evaluated at birth by the Neonatal Thyroid Screening Program, based on circulating TSH, no further measurements being made, for the same reason just indicated for the mothers.

Epidemiological studies performed in the Netherlands (12–14), United States (15), and Russia (23) have shown neurological alterations in children from mildly to moderately hypothyroxinemic mothers. Furthermore, a prospective study from Italy reported a positive correlation between iodine deficiency during the first half of gestation and the IQ score of their children (16). In addition, 68.7% presented attention deficit hyperactivity disorder. In these studies, no signs of clinical or subclinical hypothyroidism were observed in the hypothyroxinemic mothers and their children were euthyroid at birth. In agreement with the above studies, we observed that children from groups 2 and 3 showed a significant delay in neurobehavioral development compared to those of group 1.

Using iodized salt and eating seafood 2–3 days per week, a woman’s daily iodine intake would be in the order of 100–150 µg per day, approximately half the amount recently recommended during pregnancy and lactation (24, 25). Supplementation with 200 µg KI per day during pregnancy and
lactation does not block the developing thyroid gland of the fetus and neonate (3,4). In contrast, iodine supplementation from conception will ensure adequate maternal FT$_4$ during all of gestation and lactation; especially up to midgestation, when the fetal brain is particularly vulnerable to iodine deficiency (3).

Iodized salt consumption, promoted for years in areas that are now classified as free of iodine deficiency may not be sufficient for pregnant women. In Teheran and Ilan (Islamic Republic of Iran, which was declared free of iodine deficiency by the World Health Organization in 2002), as many as 28% of pregnant women had urinary iodine concentrations below the value (150 $\mu g$/L) that corresponds to the minimum accepted iodine intake of 250 $\mu g$ per day (26). Similar findings were reported from several European countries. In Poland, where iodization of household salt became obligatory in 1997, only 37% of the pregnant women had urinary iodine concentrations above 150 $\mu g$/L (27). Both a study performed in Boston, where 9% of pregnant women had urinary iodine concentrations below 50 $\mu g$/L (28), and a report of the National Health and Nutrition Examination Surveys (NHANES III) (29) have pointed out that urinary iodine is well below the values recommended by the World Health Organization and the International Council for Control of Iodine Deficiency Disorders (28-30). To prevent iodine deficiency, the American Thyroid Association (31) promoted iodine supplementation for pregnancy and lactation in the United States and Canada, recommending supplements of 150 $\mu g$ iodine per day, this being the maximum permitted in nutritional supplements for pregnancy dispensed over-the-counter. Our present data reveal that this recommendation cannot cover the iodine requirements of all pregnant women in mildly to moderately iodine-deficient countries such as Spain and the United States, among others (31). In fact, after 200 $\mu g$ KI per day supplementation from 12 to 14 gestational weeks until end of lactation to women in group 2, and from 4 to 6 gestational weeks to women in group 1, urinary iodine increased in women of these groups but still remained below the minimal values (150 $\mu g$/L) recommended by the World Health Organization (3,4): urinary iodine was on average 103.7 $\mu g$/L, with only 33.4% having more than 150 $\mu g$/L and 23.8% having less than 50 $\mu g$/L. It would be very interesting to establish an individual subject correlation between urinary iodine and offspring neurocognitive performance. However, it was not possible since urinary iodine was determined at full-term from spot samples. As already indicated above, the values obtained in spot urine samples are appropriate for epidemiological surveys of populations, but are inadequate for assessment of the iodine availability of individual members (32). In addition to a delay in iodine supplementation, differences in the degree and/or duration of iodine deficiency during gestation might also play a role. The high proportion of hypothyroxinemic women found in this study (33.0%) reveals that normal iodine intake has not been achieved and still remains a primary public health problem even in developed countries. Similar percentages of hypothyroxinemic pregnant women, or even greater (up to 50%), have been found in countries supposed to be iodine sufficient such as the United Kingdom (33).

The present results indicate a delay in neurocognitive development of 18-month-old children from mildly hypothyroxinemic women who received delayed iodine supplementation and are at risk of suffering permanent neurodevelopmental alterations. Although some of them might overcome delayed neurobehavioral development when growing in an enriched environment, the risk exists of suffering permanent neurological alterations. In fact, altered migration in the cerebral cortex was found in rats and mice that suffered mild and transient hypothyroxinemia for only 3 days at the beginning of corticogenesis (18,20). This period of time might correspond in humans to about 6 weeks of gestation, roughly from embryonic day 46 until the end of the first trimester. In addition, $T_4$ treatment of the rodents soon after inducing maternal hypothyroxinemia prevented the neurodevelopmental damage. When treatment was delayed, the alterations persisted (19).

Prospective studies on autism disorders (34,35) have found that children diagnosed at 8–18 years of age had a more retarded social development when they where 18 months old than nonautistic ones (35). We have found that five children in group 3 had a delayed development quotient, with socialization quotients more than 15 points below the fine motor quotients, suggesting that they are at risk for developing disorders of the autism spectrum. The hypothesis that these children are at risk for developing disorders of the autism spectrum is not unlikely. In fact, a recent study points out that anti-thyroid environmental substances and pollutants can affect the thyroid function during pregnancy, increasing the risk of autism in the population (36).

Differences found in gross and fine motor coordination and socialization skills, which involve neocortical areas as well as other subcortical structures as the amygdaloid complex, might indicate that early maternal hypothyroxinemia might have affected maturation and/or cortical connectivity, as occurs in animal models (18–20). In humans, these alterations might be also present in those neocortical areas, other than Broca’s and Wernicke’s, involved in language such as auditory, visual, somatosensory, and motor areas. However, no differences on language performance were found between groups, which may reflect a deficient discrimination capacity of the test in language performance in 18-month-old children. Thus, language and other complex behaviors whose neural substrates need thyroid hormone postnatally for a normal development should be tested later, when these cortical areas are in a more advanced stage of development.

In conclusion, implementation of universal salt iodization and provision of iodine supplements during pregnancy and lactation are intended to ensure that children reach their full potential development, avoiding the tragedy of a mental retardation caused by a preventable micronutrient deficiency. We have found that a delay of 6–10 weeks in iodine supplementation of pregnant women at the beginning of gestation in an area of mild iodine deficiency increases the risk of their offspring suffering permanent alterations in gross and fine motor coordination and social development. Therefore, we strongly support for this region the recommendation of a daily 200 $\mu g$ iodine supplement to all women considering conception, during pregnancy, and throughout lactation (3,4), without wasting critical weeks for confirmation that iodine intake is inadequate. Just as folates are recommended without awaiting confirmation of a possible folate deficiency, iodine supplementation likewise should not be delayed. Our data reveal that iodine supplementation is urgent and independent from possible future implementation of thyroid function screening of every woman at the beginning of pregnancy.
Acknowledgments

We thank Profs. J. Bernal, G.C. Román, and C. Sotelo and Dr. C. Berbel for critical reading of the manuscript and those parents who agreed to allow their infants to take part in this study. The help of nursing colleagues and technicians involved at different stages of this work is deeply appreciated. Supported by a grant of the Spanish Ministerio de Educación y Ciencia (SAF2006-14068) to PB.

Disclosure Statement

No competing financial interests exist.

References


Address reprint requests to:
Pere Berbel, Ph.D.
Instituto de Neurociencias de Alicante
Universidad Miguel Hernández and CSIC
Apdo. de Correos 18, Sant Joan d’Alacant
03550 Alicante
Spain

E-mail: pere.berbel@umh.es